Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PC786 in healthy adults with RSV challenge
NCT03382431Phase 2Completed
- Sponsor
- Pulmocide
- Start
- Nov 2017
- Primary completion
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial in respiratory syncytial virus infection (RSV) comparing PC786 with Placebo (2 arms). Primary endpoint: RSV viral load at Day 28. Started Nov 2017; status: completed.
02
Drugs
PC786
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT03382431.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03382431.